ADMA Biologics, Inc. (ADMA) Earnings History
Annual and quarterly earnings data from 2007 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 51.5% | 32.6% | 46.4% |
| 2023 | 34.4% | 8.4% | -10.9% |
| 2022 | 22.9% | -25.5% | -42.8% |
| 2021 | 1.4% | -72.1% | -88.5% |
| 2020 | -45.2% | -153.8% | -179.4% |
Download Data
Export ADMA earnings history in CSV or JSON format
Free sign-in required to download data
ADMA Biologics, Inc. (ADMA) Earnings Overview
As of February 28, 2026, ADMA Biologics, Inc. (ADMA) reported trailing twelve-month net income of $209M, reflecting +7.2% year-over-year growth. The company earned $0.86 per diluted share over the past four quarters, with a net profit margin of 0.5%.
Looking at the long-term picture, ADMA's historical earnings data spans multiple years. The company achieved its highest annual net income of $198M in fiscal 2024, representing a new all-time high.
ADMA Biologics, Inc. maintains positive profitability with a gross margin of 0.5%, operating margin of 0.3%, and net margin of 0.5%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including UTHR ($1.33B net income, 0.4% margin), ZLAB (-$176M net income, -0.4% margin), AMRN (-$86M net income, -0.4% margin), ADMA has outperformed on profitability metrics. Compare ADMA vs UTHR →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
18 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $198M | +800.0% | $139M | $0.81 | 46.4% | 32.6% |
| 2023 | -$28M | +57.2% | $22M | $-0.13 | -10.9% | 8.4% |
| 2022 | -$66M | +8.0% | -$39M | $-0.43 | -42.8% | -25.5% |
| 2021 | -$72M | +5.4% | -$58M | $-0.61 | -88.5% | -72.1% |
| 2020 | -$76M | -56.9% | -$65M | $-1.02 | -179.4% | -153.8% |
| 2019 | -$48M | +26.6% | -$41M | $-1.05 | -164.5% | -141.1% |
| 2018 | -$66M | -50.2% | -$60M | $-1.45 | -387.1% | -354.9% |
| 2017 | -$44M | -124.2% | -$39M | $-1.91 | -192.3% | -172.7% |
| 2016 | -$20M | -8.6% | -$17M | $-1.61 | -183.1% | -162.6% |
| 2015 | -$18M | -6.9% | -$16M | $-1.73 | -250.4% | -216.1% |
See ADMA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADMA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ADMA vs AGIO
See how ADMA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ADMA growing earnings?
ADMA EPS stands at $0.86, with +7.2% growth matching the 5-year CAGR of N/A. TTM net income is $209M. Earnings trajectory remains consistent.
What are ADMA's profit margins?
ADMA Biologics, Inc. net margin is +0.5%, with operating margin at +0.3%. Below-average margins reflect competitive or cost pressures.
How consistent are ADMA's earnings?
ADMA earnings data spans 2007-2024. The current earnings trend is +7.2% YoY. Historical data enables comparison across business cycles.